ARCHIVES

Also Von Eschenbach role in industry program raises new concerns of conflict of interest.

This article is from The Cancer Letter archive.

Vol. 31 No. 43 | November 23, 2005

Download PDF Visit The Full Archive

Related Articles

NCI spends A Third Of Its Budget On Prevention

May 15, 1992

Patient Advocacy: Breast Cancer Coalition Forms PAC To Increase Political Activities

April 18, 1997

NCCS Networker Volume 10 Issue 2, Summer/Fall 1996 Special Commemorative Issue

August 13, 1996

Preclinical Models: NCI Advisors OK Plan For Mouse Models Consortium

March 13, 1998

Inspector General’s chronology Of Events In Gallo Research

July 1, 1994

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005